...
首页> 外文期刊>Frontiers in Immunology >Immunogenic Domains and Secondary Structure of Escherichia coli Recombinant Secreted Protein Escherichia coli-Secreted Protein B
【24h】

Immunogenic Domains and Secondary Structure of Escherichia coli Recombinant Secreted Protein Escherichia coli-Secreted Protein B

机译:大肠埃希菌重组分泌蛋白B的免疫原性结构域和二级结构

获取原文
           

摘要

Several pathogenic bacteria are able to induce the attaching and effacing (A/E) lesion. The A/E lesion is caused by effector proteins, such as Escherichia coli-secreted protein B (EspB), responsible together with Escherichia coli-secreted protein D for forming a pore structure on the host cell, which allows the translocation of effector proteins. Different variants of this protein can be found in E. coli strains, and during natural infection or when this protein is injected, this leads to variant-specific production of antibodies, which may not be able to recognize other variants of this bacterial protein. Herein, we describe the production of a hybrid recombinant EspB toxin that comprises all known variants of this protein. This recombinant protein could be useful as an antigen for the production of antibodies with broad-range detection of EspB-bearing bacteria, or as an antigen that could be used in vaccine formulation to generate antibodies against different EspB variants, thereby increasing immunization potential. In addition, the recombinant protein allowed us to analyze its secondary structure, to propose the immunogenic regions of EspB variants, and also to characterize anti-EspB antibodies. Our results suggest that this hybrid protein or a protein composed of the conserved immunogenic regions could be used for a variety of clinical applications.
机译:几种致病细菌能够诱导附着和脱落(A / E)病变。 A / E病变是由效应蛋白(例如大肠杆菌分泌的蛋白B(EspB))引起的,该蛋白与大肠杆菌分泌的蛋白D一起负责在宿主细胞上形成孔结构,从而允许效应蛋白易位。可以在大肠杆菌菌株中发现该蛋白的不同变体,并且在自然感染期间或注射该蛋白时,这会导致抗体的变体特异性产生,这可能无法识别该细菌蛋白的其他变体。本文中,我们描述了包含该蛋白质所有已知变体的杂种重组EspB毒素的产生。该重组蛋白可用作抗原,用于广泛检测带有EspB的细菌,以生产抗体,或可用作抗原,用于疫苗制剂中以产生针对不同EspB变体的抗体,从而增加免疫潜力。此外,重组蛋白使我们能够分析其二级结构,提出EspB变体的免疫原性区域,并表征抗EspB抗体。我们的结果表明,这种杂合蛋白或由保守的免疫原性区域组成的蛋白可用于多种临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号